FINWIRES · TerminalLIVE
FINWIRES

US Semiconductor Sector Set for AI-Driven Acceleration, BofA Says

By

US semiconductor companies are on track for faster AI-driven sales growth and stronger returns this year as spending on AI infrastructure accelerates, BofA Securities said Wednesday in a report.

BofA raised its 2030 estimate for the AI data-center systems market to $1.7 trillion from $1.4 trillion, reflecting a stronger outlook for AI-related capital spending.

Despite investor concerns about whether elevated capital expenditures can last, BofA said the near term still looks constructive as companies such as OpenAI and Anthropic, along with expected IPO activity, support a healthier demand backdrop.

The sector may also see efficiency gains in 2027 as new compute and memory architectures roll out, the report said.

Memory demand is expected to continue outpacing supply as AI projects scale up, with pricing likely to remain firm, the report said. BofA lifted Micron Technology's (MU) price target to $950 from $500, citing a "much stronger midterm pricing outlook."

For top pick Nvidia (NVDA), BofA raised its price target to $320 from $300, pointing to upcoming catalysts including earnings, the Computex trade show and a potential new CPU launch.

BofA increased Marvell Technology's (MRVL) price target to $200 from $125, citing strong optics demand tied to AI buildouts and momentum in custom silicon.

The firm raised Advanced Micro Devices' (AMD) price target to $500 from $450, citing recent CPU strength and potential catalysts at the company's July analyst day, along with more data-center opportunities.

For Broadcom (AVGO), BofA said recent frame contracts with Alphabet's (GOOGL) Google and Meta Platforms (META) help lock in 2027 demand, with potential upside to the consensus estimate of $110 billion in AI sales.

Price: $794.01, Change: $+27.43, Percent Change: +3.58%

Related Articles

Wire

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.Gyre shares rose 1.4% in after-hours trading.

$GYRE
Wire

Evolution Petroleum Swings to Fiscal Q3 Loss as Revenue Falls; Shares Drop After Hours

Evolution Petroleum (EPM) reported a fiscal Q3 adjusted loss late Tuesday of $0.09 per diluted share, swinging from earnings of $0.02 a year earlier.Analysts polled by FactSet expected earnings of $0.02.Revenue in the three months ended March 31 fell to $20.2 million from $22.6 million a year earlier.Analysts surveyed by FactSet expected $21.3 million.Evolution shares fell 7.3% in after-hours trading.

$EPM
Wire

Arteris Q1 Adjusted Loss Narrows, Revenue Rises; Shares Gain After Hours; CFO to Retire

Arteris (AIP) reported a Q1 adjusted loss late Tuesday of $0.03 per diluted share, narrowing from the loss of $0.09 a year earlier.Four analysts polled by FactSet expected a loss of $0.07.Revenue in the three months ended March 31 rose to $22.9 million from $16.5 million a year earlier.Four analysts surveyed by FactSet expected $21 million.The company expects revenue of $23 million to $24 million in Q2 and $91 million to $95 million in the full year. Four analysts expect $22 million in Q2 and $91 million in the full year.Arteris shares rose 7.9% in after-hours trading.The company also said Chief Financial Officer Nicholas Hawkins plans to retire effective Aug. 31, and the board has started a search for a new CFO.

$AIP